Comments
Loading...

Relmada Therapeutics Analyst Ratings

RLMDNASDAQ
Logo brought to you by Benzinga Data
$0.2601
-0.01-4.52%
At close: -
$0.2717
0.014.46%
After Hours: 7:15 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$26.00
Lowest Price Target1
$1.00
Consensus Price Target1
$8.83

Relmada Therapeutics Analyst Ratings and Price Targets | NASDAQ:RLMD | Benzinga

Relmada Therapeutics Inc has a consensus price target of $8.83 based on the ratings of 8 analysts. The high is $26 issued by Mizuho on June 15, 2023. The low is $1 issued by Mizuho on December 5, 2024. The 3 most-recent analyst ratings were released by Mizuho, Leerink Partners, and Jefferies on December 5, 2024, December 4, 2024, and September 17, 2024, respectively. With an average price target of $5 between Mizuho, Leerink Partners, and Jefferies, there's an implied 1740.26% upside for Relmada Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
2
Dec 24
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.0
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Mizuho
Leerink Partners
Jefferies
Goldman Sachs
Mizuho

1calculated from analyst ratings

Analyst Ratings for Relmada Therapeutics

Buy NowGet Alert
12/05/2024Buy Now268.05%Mizuho
Uy Ear64%
$23 → $1DowngradeOutperform → NeutralGet Alert
12/04/2024Buy Now268.05%Leerink Partners
Marc Goodman73%
$10 → $1DowngradeOutperform → Market PerformGet Alert
09/17/2024Buy Now4684.69%Jefferies
Andrew Tsai29%
$3.5 → $13UpgradeHold → BuyGet Alert
06/05/2024Buy Now636.11%Goldman Sachs
Andrea Tan40%
$3 → $2DowngradeNeutral → SellGet Alert
06/15/2023Buy Now9469.38%Mizuho
Vamil Divan74%
→ $26ReiteratesBuy → BuyGet Alert
01/23/2023Buy Now3580.53%SVB Leerink
Marc Goodman73%
$42 → $10MaintainsOutperformGet Alert
10/14/2022Buy Now2844.42%Goldman Sachs
Andrea Tan40%
→ $8DowngradeBuy → NeutralGet Alert
10/14/2022Buy NowGuggenheim
Yatin Suneja47%
DowngradeBuy → NeutralGet Alert
10/13/2022Buy NowOppenheimer
Jay Olson61%
DowngradeOutperform → PerformGet Alert
09/23/2022Buy Now29712.29%Goldman Sachs
Andrea Tan40%
$49 → $81MaintainsBuyGet Alert
09/06/2022Buy Now21983.18%Guggenheim
Yatin Suneja47%
$50 → $60MaintainsBuyGet Alert
05/09/2022Buy Now23455.39%Oppenheimer
Jay Olson61%
$75 → $64MaintainsOutperformGet Alert

FAQ

Q

What is the target price for Relmada Therapeutics (RLMD) stock?

A

The latest price target for Relmada Therapeutics (NASDAQ:RLMD) was reported by Mizuho on December 5, 2024. The analyst firm set a price target for $1.00 expecting RLMD to rise to within 12 months (a possible 268.05% upside). 4 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Relmada Therapeutics (RLMD)?

A

The latest analyst rating for Relmada Therapeutics (NASDAQ:RLMD) was provided by Mizuho, and Relmada Therapeutics downgraded their neutral rating.

Q

When was the last upgrade for Relmada Therapeutics (RLMD)?

A

The last upgrade for Relmada Therapeutics Inc happened on September 17, 2024 when Jefferies raised their price target to $13. Jefferies previously had a hold for Relmada Therapeutics Inc.

Q

When was the last downgrade for Relmada Therapeutics (RLMD)?

A

The last downgrade for Relmada Therapeutics Inc happened on December 5, 2024 when Mizuho changed their price target from $23 to $1 for Relmada Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Relmada Therapeutics (RLMD)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Relmada Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Relmada Therapeutics was filed on December 5, 2024 so you should expect the next rating to be made available sometime around December 5, 2025.

Q

Is the Analyst Rating Relmada Therapeutics (RLMD) correct?

A

While ratings are subjective and will change, the latest Relmada Therapeutics (RLMD) rating was a downgraded with a price target of $23.00 to $1.00. The current price Relmada Therapeutics (RLMD) is trading at is $0.27, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch